Factors associated with creatinine clearance changes following TLD drug regimen in ARV Clinic Thalang Hospital, Phuket
Keywords:
creatinine clearance changes, estimated Glomerular Filtration Rate (eGFR), ARV Clinic Thalang Hospital, TLD drug regimenAbstract
Abstract
This Retrospective cohort study aimed to study factors association with creatinine clearance changes following TLD drug regimen in ARV Clinic Thalang Hospital, Phuket. Population in this study consisted of 522 HIV patients in ARV Clinic Thalang Hospital, Phuket from 2022 to 2023, and the sample size calculating used Cochran’s (1977) formula for 222 cases, and systematic random sampling was determined for collecting data. Data collected by electronic medical record composed of 3 parts including, characteristics, laboratory examination before and after using TLD drug regimen. In addition to check standardization and validity was checked by 3 experts and testing reliability by Cronbach’s coefficient alpha more than 0.5. Data analyzed using paired t-test found that estimated Glomerular Filtration Rate (eGFR) average score decreasing with statistic significant (P-value<0.001). The average eGFR following TLD drug regimen 9 months was changed from 99.98 ml/min/1.73m2 SD 15.60 to 83.86 ml/min/1.73m2 SD 18.12. Data analyzed using statistical as Pearson product moment correlation coefficient and Stepwise multiple regression analysis. Prediction model analyzed reported that factor association with creatinine clearance changes following TLD drug regimen, including age (P-value=0.024) and prior HIV drug regimen (P-value=0.035)
References
เอกสารอ้างอิง
ศูนย์รวมรวบข้อมูลสารสนเทศด้านเอชไอวีของประเทศไทย (2022). Thailand: HIV Info Huสถานการณ์โรค
เอชไอวีประเทศไทย [updated 2022 April 27; cited 2022 Nov 27]. Available from:
https://hivhub.ddc.moph.go.th/epidemic.php
กรมควบคุมโรค. แนวทางการตรวจรักษาและป้องกันการติดเชื้อ เอชไอวีประเทศไทย ปี 2564/65 (2565).
พิมพ์ครั้งที่ 1. กรุงเทพฯ: โรงพิมพ์ ชุมนุมสหกรณ์การเกษตรแห่งประเทศไทยจำกัด; 2565. 292
The Joint United Nations Program on HIV/AIDS. [UNAIDS] (2022). [cited 2022 Nov 4]. Available
from: https://unaids.org/en
Koteff J, Borland J, Chen S, et al (2013). A phase 1 study to evaluate the effect of dolutegravir
on renal function via measurement of iohexol and para-aminohippurate clearance in
healthy subjects. Brit J Clin Pharmacol. 75(4):990–996
Wassner C, Bradley N, Lee Y (2020). A review and clinical understanding of tenofovir: tenofovir
disoproxil fumarate versus tenofovir alafenamide. J Int Assoc Provid AIDS Care. 2020;
:2325958220919231
Shirley X. Jiang, John Duncan, Hin Hin Ko (2023). “Acquired Fanconi Syndrome from Tenofovir
Treatment in a Patient with Hepatitis B", Case Reports in Hepatology, vol. 2023.
https://doi.org/10.1155/2023/6158407
Doshi, S., Ucanda, M., Hart, R., Hou, Q., Terzian, A. S., & DC Cohort Executive Committee (2019).
Incidence and Risk Factors for Renal Disease in an Outpatient Cohort of HIV-Infected
Patients on Antiretroviral Therapy. Kidney international reports, 4(8), 1075–1084.
https://doi.org/10.1016/j.ekir.2019.04.024
Li, Y., Shlipak, M. G., Grunfeld, C., & Choi, A. I. (2012). Incidence and risk factors for acute kidney
injury in HIV Infection. American journal of nephrology, 35(4), 327–334.
https://doi.org/10.1159/000337151
Cottrell ML, Hadzic T, Kashuba AD (2013). Clinical pharmacokinetic, pharmacodynamic and
drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet.
:981-94.
Kolakowska A, Maresca AF, Collins IJ, Cailhol J (2019). Update on adverse effects of HIV integrase inhibitors. Curr Treat Options Infect Dis. 11:372-87.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
